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In this study we address two major issues related to the current development process of therapeutic proteins 
and their characterization. First, due to limited samples amounts, the selection of lead molecules in the early 
stages is often based on the results from a limited physicochemical characterization. The latter can be based on 
measurements of only 2-3 parameters, e.g. protein melting temperature, protein aggregation temperature, and 
is usually performed in only one buffer, e.g. PBS. The hypothesis we present is that such approach can lead to 
the rejection of lead candidates that can still be manufacturable and can move on to clinical trials. The second 
matter we address are the often-reported correlations between protein physicochemical parameters in the 
literature. We propose that such correlations can be found only in a small sample population, e.g. one protein in 
different solution conditions or different proteins from the same class. However, we expect that such correlations 
would not be valid in a large population, including various protein structures and solution conditions.  
In order to address the above-mentioned issues, we created the PIPPI consortium 
(http://www.pippi.kemi.dtu.dk) and applied systematic approach to map the physicochemical properties of a wide 
range of proteins and extensively study their stability as a function of the solution conditions. 
We show that promising therapeutic protein lead candidate can appear as non-manufacturable when only 
limited physicochemical characterization is performed, e.g. a few methods are used and only a few solution 
conditions are tested. Therefore, the rejection rate during early-stage development can be improved by more 
thorough physicochemical characterization. Moreover, only weak linear correlations between biophysical 
properties of proteins are observed in a large populations. This suggests that the often-reported correlations 
between parameters describing the protein stability are not representative of a global population. Understanding 
the connections between various physiochemical parameters would require a systematic database which is 
currently in development by the PIPPI consortium. 
